title: [Splenic marginal zone lymphoma].
abstract: Splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes is a low-grade malignant lymphoma, which primarily involves the spleen, the bone marrow and the blood. Even though the prognosis of the disease is good and there is a long overall survival, about two thirds of the patients will require treatment and in 10% of the patients the lymphoma will transform into a high-grade malignant lymphoma. The treatment of SMZL remains empirical, since there is lack of large, prospective studies. Without such studies, the best treatment modality cannot be established.
authors.affiliation: Hæmatologisk Afdeling, Herlev Hospital, Herlev Ringvej 75, Herlev. stamatiskostas@msn.com
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Dimopoulos
authors.forename: Michael
authors.initials: M
authors.lastname: Pedersen
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000145:classification / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D008297:Male; D011379:Prognosis; D013156:Splenectomy; D013160:Splenic Neoplasms / Q000145:classification / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D016019:Survival Analysis; D057832:Watchful Waiting
chemical_list: D000970:Antineoplastic Agents